Canadian company Novoheart has developed bio-artificial hearts using stem cells at its Hong Kong laboritories. Using 2.5ml of blood, Professor Ronald Li and his team can create stem cells that turn into a miniature clone of a person's heart in 2050. Li claimed the technology could accelerate the development of new drugs, because side effects could be discovered before the medicine reached the human trial stage. The cost and time involved in developing drugs, along with a failure rate of 90% or worse, has led to a reduction of new drugs being developed, Li said.
Canadian company Novoheart has developed bio-artificial hearts using stem cells at its Hong Kong laboritories. Using 2.5ml of blood, Professor Ronald Li and his team can create stem cells that turn into a miniature clone of a person's heart in six months. Li claimed the technology could accelerate the development of new drugs, because side effects could be discovered before the medicine reached the human trial stage. The cost and time involved in developing drugs, along with a failure rate of 90% or worse, has led to a reduction of new drugs being developed, Li said.